Open AccessPlasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy
Author(s) -
Lauren R. Cirrincione,
Anthony T. Podany,
Joshua P. Havens,
Sara H Bares,
Shetty Ravi Dyavar,
Yeongjin Gwon,
Trevor Johnson,
N. Jean Amoura,
Courtney V. Fletcher,
Kimberly K Scarsi
Publication year - 2020
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkaa016
Subject(s) - emtricitabine , tenofovir , pharmacokinetics , medicine , pharmacology , pre exposure prophylaxis , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , virology , men who have sex with men , syphilis
Transwomen have an increased risk of HIV acquisition compared with other adults. Drug-drug interactions between pre-exposure prophylaxis (PrEP) and gender-affirming therapy are cited as a reason for poor PrEP uptake among transwomen. We evaluated plasma tenofovir and emtricitabine pharmacokinetics and their active intracellular anabolites, tenofovir-diphosphate and emtricitabine-triphosphate, in transwomen receiving feminizing hormones.